Comments on the Study “Adapting the Bellmunt Risk Score for Prognostic Stratification in Metastatic Castration‐Sensitive Prostate Cancer”

Détails bibliographiques
Auteur principal:	Xian Wen
Format:	Artículo Open Access
Publié:	Wiley 2026
Sujets:	The Prostate
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Directed Evolution Restored Castrate Sensitivity in a Patient With Castrate Resistant Metastatic Prostate Cancer
par: Robert A. Gatenby, et autres
Publié: (2025)

Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
par: Mitsuhisa Nishimoto, et autres
Publié: (2025)

Number of Prescription Medications and Overall Survival in Metastatic Castrate‐Resistant Prostate Cancer
par: Carley R. Pickett, et autres
Publié: (2024)

Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone‐Sensitive Prostate Cancer
par: Umang Swami, et autres
Publié: (2026)

A Two‐Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone‐Sensitive Prostate Cancer
par: Koichiro Kurokawa, et autres
Publié: (2026)

Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer
par: Kazuma Yukihiro, et autres
Publié: (2026)

Association of Weight Loss and BMI on PSA Levels and Overall Survival in Veterans With Metastatic Castrate‐Resistant Prostate Cancer
par: Nicholas Fedele, et autres
Publié: (2025)

Castration Resistance Accelerates Prostate Cancer Kinetics
par: Sheila Jonnatan, et autres
Publié: (2026)

Comments on the Study “Evaluating the Efficacy of Barley Water in Alleviating Radiotherapy‐Induced Dysuria in Prostate Cancer Patients”
par: Leibo Wang, et autres
Publié: (2026)

Bone Metastasis Distribution Matters: Prognostic Effect of the Axial‐to‐Peripheral Ratio in Metastatic Hormone‐Sensitive Prostate Cancer
par: Ali Fuat Gürbüz, et autres
Publié: (2026)

Prognostic Nutritional Index as a Biomarker in Metastatic Hormone‐Sensitive Prostate Cancer: Impact on Survival and Treatment Optimization
par: Muhammet Bekir Hacioglu, et autres
Publié: (2025)

Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer
par: András Horváth, et autres
Publié: (2025)

Outcome of Subsequent Therapies After 177Lu‐Vipivotide Tetraxetan for Metastatic Castrate‐Resistant Prostate Cancer: A Tertiary Cancer Center Experience
par: Meryam Losee, et autres
Publié: (2025)

Refining the CHAARTED Classification: Clinical Utility of a Novel Integrated Risk Stratification Model Incorporating Gleason Grade and Biochemical Markers in Japanese Patients With Metastatic Hormone‐Sensitive Prostate Cancer
par: Takanori Tokunaga, et autres
Publié: (2025)

Beyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer
par: Anwar E. Ahmed, et autres
Publié: (2025)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy
par: Takeshi Tsutsumi, et autres
Publié: (2026)

Prognostic Impact of Initial Prostate Specific Antigen Half‐Life After Abiraterone Acetate in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: Who May Need Triplet Therapy?
par: Kotaro Suzuki, et autres
Publié: (2026)

Prostate‐Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone‐Sensitive Prostate Cancer Treated With Apalutamide
par: Christian Andrés Martínez Osorio, et autres
Publié: (2025)

Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration‐Resistant Prostate Cancer: A Real‐World Multi‐Intuitional Analysis
par: Kotaro Suzuki, et autres
Publié: (2025)

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study
par: Himawari Asanuma, et autres
Publié: (2026)

Baseline Imaging Derived Factors of Response Following [225Ac]Ac‐J591 Therapy in Metastatic Castration‐Resistant Prostate Cancer: A Lesion Level Analysis
par: Judith Stangl‐Kremser, et autres
Publié: (2025)

Establishment and Characterization of Patient‐Derived Xenograft Organoids for Personalized Treatment of Castration‐Resistant Prostate Cancer
par: Takuro Sunada, et autres
Publié: (2026)

Restoration of Mitochondrial Function: A Metabolic Perspective on “Directed Evolution” in Castration‐Resistant Prostate Cancer
par: Po‐Jung Su, et autres
Publié: (2026)

Comparative Effectiveness of First‐Line Treatments for Castration‐Resistant Prostate Cancer: A Large‐Scale Retrospective Study in Japan
par: Akihito Hashizume, et autres
Publié: (2025)

Real‐World Treatment Patterns Before and After Metastatic Castration–Resistant Prostate Cancer in Japan: Retrospective Analysis Using a Hospital‐Based, Multicenter Database
par: Masaki Shiota, et autres
Publié: (2026)

The Clinical Significance of Gallium‐68 PSMA‐11 PET‐Derived SUVmax in the Management of Metastatic Hormone‐Sensitive Prostate Cancer
par: Cevat İlteriş Kıkılı, et autres
Publié: (2026)

Evaluating the Prognostic Impact of Apparent Diffusion Coefficient in Definitive Radiotherapy for Gleason Score 7 Prostate Cancer Patients
par: Cem Onal, et autres
Publié: (2024)

Comprehensive Genomic Profiling Testing for Castration‐Resistant Prostate Cancer in Advanced Elderly Patients: A Single‐Center Retrospective Cohort Study
par: Takafumi Fukushima, et autres
Publié: (2025)

Downregulation of NONO Suppresses Proliferation, Migration, and Invasion in Metastatic Prostate Cancer
par: Anna‐Lena Lemster, et autres
Publié: (2025)

Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single‐Institution Pilot Study
par: Cameron J. Britton, et autres
Publié: (2025)

Comparative Evaluation of Detection Rates for Clinically Significant Prostate Cancer Using MRI‐Targeted Biopsy Alone Versus in Combination With Systematic Biopsies: Development of a Risk‐Stratification Scoring System
par: Toshifumi Takahashi, et autres
Publié: (2024)

Towards Precision Oncology: A New Predictive Machine Learning Model for Early Progression to Castration Resistant Prostate Cancer
par: Miguel Ángel Gómez‐Luque, et autres
Publié: (2025)

Genetics‐Driven, Intensity‐Modulated Adaptive Management of Patients With Metastatic Prostate Cancer
par: Reynier D. Rodriguez Rosales, et autres
Publié: (2025)

Bellmunt risk score as a survival predictor in patients with metastatic castration‐resistant prostate cancer
par: Thomas Büttner, et autres
Publié: (2024)

The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
par: Yifu Shi, et autres
Publié: (2025)

Diagnostic and Prognostic Value of cfDNA Concentration and Fragmentation in Prostate Cancer
par: Marta Victoria Lorenzo‐Sánchez, et autres
Publié: (2025)

Comment on “Robotic‐Assisted Radical Prostatectomy in the Elderly Patient—A Study of Functional, Surgical, and Oncological Outcomes in an Australian Cohort”
par: Xian Wen
Publié: (2026)

A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate‐Resistant Prostate Cancer (TRICREST)
par: Kenrick Ng, et autres
Publié: (2025)

Effects of Concurrent Administration of Spironolactone in Veterans with Metastatic Prostate Cancer Receiving Abiraterone: A Real‐World Retrospective Study
par: Erum Z. Whyne, et autres
Publié: (2024)

Clinicopathological Significance of Extranodal Adipose Tissue Invasion in Metastatic Lymph Nodes in Patients With Prostate Cancer
par: Hirotaka Nagasaka, et autres
Publié: (2024)

Documents similaires

Documents similaires